Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

1993 • 396 citations

Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B.

1992 • 168 citations

Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

1994 • 167 citations

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas

1994 • 159 citations

Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.

1990 • 147 citations

The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.

1991 • 147 citations

Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based Chemotherapy

1994 • 140 citations

Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.

1997 • 137 citations

Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.

1990 • 131 citations

FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro.

1991 • 124 citations

Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.

1994 • 107 citations

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

1995 • 96 citations

Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.

1995 • 84 citations

The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

1995 • 79 citations

Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer

1994 • 71 citations

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

1996 • 68 citations

Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival

1993 • 63 citations

Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1.

1992 • 55 citations

Macrophage colony-stimulating factor and granulocyte-macrophage colony- stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes

1993 • 37 citations

Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF-1

1997 • 32 citations

Immunohistochemical Study of Tumor Cell-associated Plasminogen Activators and Plasminogen Activator Inhibitors in Lung Carcinomas

1993 • 27 citations

pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.

1997 • 15 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...